Details for Patent: 8,993,549
Which drugs does patent 8,993,549 protect, and when does it expire?
Patent 8,993,549 protects BIJUVA and is included in one NDA.
This patent has one hundred and sixty-seven patent family members in twenty-one countries.
Summary for Patent: 8,993,549
| Title: | Natural combination hormone replacement formulations and therapies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | TherapeuticsMD Inc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/475,864 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,993,549 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Dosage form; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 8,993,549: Estradiol-Progesterone Formulation Scope, Exclusivity and Patent LandscapeUS Patent 8,993,549 protects oral pharmaceutical compositions that combine solubilized estradiol with suspended progesterone in a lipid-based solubilizing system containing C6-C12 fatty-acid mono- or diglycerides. The claims are formulation claims, not claims to estradiol, progesterone, hormone replacement therapy generally, or a particular clinical indication. The patent’s commercial relevance is its apparent coverage of the Bijuva-type softgel formulation, including estradiol/progesterone strengths corresponding to 0.5 mg/100 mg and 1 mg/100 mg products. The strongest infringement risk arises where a competing product uses the same mixed physical state, lipid excipient class, and dosage-form architecture. What does US Patent 8,993,549 protect?The patent protects a composition with four central technical limitations:
The claims therefore target a mixed formulation in which estradiol is substantially dissolved while progesterone remains at least partly suspended. That distinction separates the invention from a fully solubilized dual-hormone formulation and from a simple physical mixture of two finished drug substances. The patent is formulation-specific. A product may contain the same active ingredients and dosage strengths yet avoid literal infringement if it does not satisfy the specified solubilization, suspension, dispersion, or excipient limitations. How are the independent claims structured?
Claims 1, 7 and 13 are composition claims. They do not require a method of treatment, administration step, pharmacokinetic result, or clinical outcome. Claim 1 is structurally the broadest. It covers:
provided the relevant agent contains an ester of a C6-C12 fatty acid. Claim 7 narrows the composition to a monoglyceride. Claim 13 narrows it to a diglyceride. The three independent claims create overlapping protection and reduce the impact of a design-around that changes the glyceride category. What do the dependent claims add?
The dosage-strength claims are broad at their lower thresholds. They are not limited to the marketed 0.5 mg/100 mg and 1 mg/100 mg strengths. The ratio claims are more commercially focused. The 100:1 and 200:1 ratios correspond to the principal Bijuva strengths. The 14-day nonprecipitation limitation may be important in litigation because it introduces a testable product-performance requirement. A challenger may dispute the assay method, storage conditions, sampling protocol, or meaning of “does not precipitate.” A patent owner would likely rely on formulation testing and stability data to establish compliance. What formulations are protected by US 8,993,549?The claim language covers a formulation in which the lipid vehicle performs different functions for the two hormones:
The C6-C12 limitation is directed to medium-chain fatty-acid chemistry. Potentially relevant excipient classes include glycerides derived from caproic, caprylic, capric or lauric acid, subject to the precise chemical identity and formulation concentration. The claims do not expressly require:
A formulation using a triglyceride rather than a mono- or diglyceride may present a design-around opportunity, but the analysis depends on the actual composition, impurities, excipient characterization and any applicable doctrine-of-equivalents theory. How strong is the patent estate for Bijuva-type products?The patent is strongest against a copycat that reproduces all of the following:
The estate is weaker against a product that changes the physical formulation architecture. Potential alternatives include:
The patent’s protection is therefore commercially meaningful but not technology-wide. It does not prevent all generic estradiol/progesterone products. It primarily creates a barrier around a specific oral softgel formulation. When does US Patent 8,993,549 lose exclusivity?The patent has a nominal 20-year term measured from its earliest effective nonprovisional priority date. Public patent records associate the family with a March 2009 priority date, producing a nominal expiration date in March 2029, subject to patent-term adjustment, terminal disclaimers, fee status and any applicable patent-term extension.[1] The patent does not receive the five-year restoration available to a new chemical entity because estradiol and progesterone were previously known active ingredients. Any regulatory exclusivity for an approved product is separate from the patent term.
FDA approved Bijuva under NDA 210731 in 2018 as an oral combination of estradiol and progesterone for moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus.[2] Regulatory exclusivity and Orange Book listing must be analyzed separately from the patent’s expiration date. What is the Orange Book status of US 8,993,549?US Patent 8,993,549 has been associated with the Bijuva product and its formulation protection in FDA patent-listing materials. The Orange Book identifies patents submitted by an NDA holder as covering the drug substance, drug product or method of use. A formulation patent of this type is generally evaluated as a drug-product patent rather than a drug-substance patent.[3] The commercial consequences are:
Orange Book listings do not establish validity. They identify patents that FDA has accepted for listing based on the NDA holder’s submission and FDA’s administrative review. Are there Paragraph IV challenges to Bijuva or this patent?A Paragraph IV challenge would require an ANDA applicant to assert that US 8,993,549 is invalid, unenforceable or not infringed. The most credible challenge theories would focus on: Lack of novelty or obviousnessEarlier hormone formulations may disclose estradiol, progesterone and lipid excipients individually. The challenger would need to show that the claimed combination, including the 90% estradiol-solubilization threshold and suspended progesterone architecture, was disclosed or would have been obvious. IndefinitenessPotential disputes could involve:
The claims contain functional and qualitative language, but that language is not automatically indefinite. The specification, examples and analytical methods would determine whether a skilled formulator could apply the limitations with reasonable certainty. Written description and enablementA challenger could argue that the claims cover an undue range of C6-C12 mono- and diglyceride systems or dosage combinations not adequately supported by the specification. The patent owner would rely on formulation examples, stability data and the ordinary skill of pharmaceutical scientists. NoninfringementNoninfringement is likely to be the most commercially practical route. A generic manufacturer could alter the lipid vehicle, hormone physical state, capsule design or dosage-unit structure rather than reproduce every limitation. The existence and status of any individual Paragraph IV notice letter, district-court complaint or settlement must be confirmed through FDA ANDA records and federal court filings. The patent claims alone do not establish that a Paragraph IV dispute has occurred. What patent litigation affects US 8,993,549?The patent should be reviewed in three litigation layers:
For this patent, the key litigation evidence would include:
A generic formulation may be difficult to evaluate from the public label alone. The composition and manufacturing information in an ANDA is not fully public. That limits the ability to determine infringement before litigation or an authorized settlement. Which companies are challenging the Bijuva patent estate?Bijuva’s competitive risk is primarily generic, not biosimilar. Estradiol and progesterone are small-molecule active ingredients, so a biosimilar pathway under the Public Health Service Act is not applicable. A competitor would ordinarily use an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[2] Potential entrants include manufacturers with experience in:
The absence of an identified challenger in the supplied record does not establish that no Paragraph IV notice exists. FDA Orange Book updates and federal docket records control the current litigation picture. How does US 8,993,549 compare with competing patent strategies?
US 8,993,549 has greater value than a narrow dosage claim because it ties together composition, physical state and excipient chemistry. Its value is lower than a valid compound patent because a competitor can potentially design around the formulation while retaining the same active ingredients. What generic launch scenarios exist?Launch after patent expirationA generic may launch after expiration if FDA requirements are satisfied and no other listed patent or exclusivity blocks approval. The expected ordinary patent endpoint is in 2029, subject to the official patent record. Paragraph IV launchAn ANDA applicant may launch after a favorable judgment, settlement authorization, or expiration of the relevant stay. The applicant could pursue a formulation that avoids the mono- or diglyceride limitations or the claimed physical-state requirements. At-risk launchAn applicant may launch before final resolution, exposing itself to damages and injunctive relief if the patent is found valid, enforceable and infringed. This is less attractive where the formulation closely tracks the patented product. Non-infringing formulation launchA competitor may seek approval for a product with different excipient chemistry or separate dosage units. This route reduces patent risk but may increase development, bioequivalence and commercial-substitutability risk. What revenue exposure does the patent create?The patent has its highest revenue relevance for products that depend on the oral combined estradiol/progesterone softgel format. It does not block:
Revenue exposure therefore depends on how much of the product’s sales derive from the protected formulation rather than from the active ingredients generally. Generic entry could reduce price and market share materially if the competing product is therapeutically substitutable and receives AB-rated approval. The patent estate may delay direct substitution even after regulatory approval if additional Orange Book patents remain listed. A full launch analysis must therefore assess the entire Bijuva patent family, not US 8,993,549 in isolation. Key Takeaways
FAQsIs US Patent 8,993,549 a drug patent or a formulation patent?It is a formulation patent. It does not claim estradiol or progesterone as chemical entities. It claims a specific pharmaceutical composition and its physical and excipient characteristics. Does the patent cover every estradiol and progesterone combination?No. A competing product must satisfy the claimed solubilization, suspension, dispersion and glyceride limitations, or a court must find infringement under the doctrine of equivalents. Can a generic avoid the patent by using a triglyceride?Possibly. The claims expressly identify monoglycerides and diglycerides, while a triglyceride-only formulation may fall outside the literal claim language. The complete formulation and any equivalent-function analysis remain material. Does a gelatin capsule alone infringe US 8,993,549?No. The gelatin-capsule limitation appears only in dependent claims. The composition must also satisfy the independent claim requirements. Is a biosimilar required to compete with Bijuva?No. Estradiol and progesterone are small-molecule drugs. A competing oral combination would generally use the ANDA pathway rather than the biosimilar pathway. References
More… ↓ |
Drugs Protected by US Patent 8,993,549
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | BIJUVA | estradiol; progesterone | CAPSULE;ORAL | 210132-002 | Dec 28, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Mayne Pharma | BIJUVA | estradiol; progesterone | CAPSULE;ORAL | 210132-001 | Oct 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,993,549
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2782584 | ⤷ Start Trial | 301153 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | 2021C/558 | Belgium | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | 122021000080 | Germany | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | LUC00245 | Luxembourg | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
